ACI-35, an alternative vaccination agent, was initially developed by AC Immune and later licensed by Janssen. ACI-35 employs a liposomebased delivery strategy to anchor a tau fragment (393–408) with several phosphorylated serine residues (S396/S404) known to be pathologically phosphorylated by GSK3 kinases. [97] In P301 L mice, treatment with ACI-35 showed robust immunogenicity, with a reduction in phosphorylated forms of tau, and improvement in motor deficits [97]. ACI-35 started an international Phase 1 clinical trial in patients with mild to moderate AD (ISRCTN13033912), which concluded in June 2017, but results have not been announced.
